High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 30, 1997

Primary Completion Date

August 31, 2002

Study Completion Date

January 31, 2003

Conditions
Breast Cancer
Interventions
BIOLOGICAL

filgrastim

10 mcg/kg/d, day 2 through last day of leukapheresis

DRUG

carboplatin

18 AUC IV, approximately days 21, 42

DRUG

cyclophosphamide

4 gm/m2 IV, day 1

DRUG

melphalan

140 mg/m2 IV , approximately day 63

DRUG

paclitaxel

170 mg/m2 IV day 1

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (14)

10016

Stem Cell Sciences, New York

10595

New York Medical College, Valhalla

14642

University of Rochester School of Medicine, Rochester

19104

University of Pennsylvania Cancer Center, Philadelphia

19140

Temple University Cancer Center, Philadelphia

33313

Bone Marrow Stem Cell Transplant Institute of Florida, Fort Lauderdale

38104

Methodist Hospital-Central Unit, Memphis

53226

Medical College of Wisconsin, Milwaukee

60068

Lutheran General Cancer Care Center, Park Ridge

60637

University of Chicago Cancer Research Center, Chicago

92037

Scripps Clinic, La Jolla

92093

University of California San Diego, La Jolla

20307-5000

Walter Reed Army Medical Center, Washington D.C.

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00003392 - High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter